Avidbiotics Corporation

South San Francisco, CA 94080

SBIR Award Summary

Total Number of Awards 13
Total Value of Awards $4.54MM
First Award Date 05/01/06
Most Recent Award Date 09/15/13

Key Personnel

Last Name Name Awards Contact
Martin David William Martin 10
Scholl Dean M Scholl 3

13 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/15/13 - 09/14/14

DESCRIPTION (provided by applicant): Monoclonal antibodies targeting tumor associated antigens (TAA's) have since 1997, provided safe and efficacious human cancer therapeutics. More recently, bispecific antibodies or bispecific antibody fragments that promote immunologic synapses between cells of the innate immune system and malignant cells have...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/01/13 - 08/31/14

DESCRIPTION (provided by applicant): The ultimate goal of this proposal and any subsequent phase II proposal is to develop a unique protein agent to prevent Clostridium difficile associated diseases in those patients at high risk rather than wait to treat their dangerous and costly infections. We aim in this SBIR phase I project to determine the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 09/26/12 - 08/31/13

DESCRIPTION (provided by applicant): The ultimate goal of this proposal and any subsequent phase II proposal is to develop a unique protein agent to prevent Clostridium difficile associated diseases in those patients at high risk rather than wait to treat their dangerous and costly infections. We aim in this SBIR phase I project to determine the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 08/10/11 - 06/30/12

DESCRIPTION (provided by applicant): Our overall Goal is to develop our bactericidal R-type pyocin targeting E.coli O157:H7, as a specific therapeutic against infection and contamination. Enterohemorrhagic E. coli (EHEC) are a group of food- and waterborne pathogens that cause illnesses ranging from non-bloody diarrhea to hemolytic uremic syndro...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 05/01/11 - 04/30/13

DESCRIPTION (provided by applicant): Acinetobacter baumannii (A. baumannii) is a human pathogen responsible for recent increases in nosocomial infections of both military and civilian populations. Further emergence of the pathogen's broad resistance to available antibiotics has emphasized the need for truly novel antibacterial therapeutics. We h...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 04/01/11 - 12/31/12

DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop a platform that broadly enables the generation of a new class of anti-viral therapeutics that recruit and activate the innate immunity system to attack specifically human cells infected with targeted viral pathogens. The platform deploys a recently discover...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/12

DESCRIPTION (provided by applicant): In our Phase 1 project we have developed R-type pyocins, targetable bactericidal proteins, that kill the plague bacterium, Yersinia pestis, in vitro and are not sensitive to the mechanisms that bacteria use to resist antibiotics. Thus, these agents are candidates for protecting or treating humans exposed to p...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 08/01/10 - 06/30/12

DESCRIPTION (provided by applicant): Our overall Goal is to develop our bactericidal R-type pyocin targeting E.coli O157:H7, as a specific therapeutic against infection and contamination. Enterohemorrhagic E. coli (EHEC) are a group of food- and waterborne pathogens that cause illnesses ranging from non-bloody diarrhea to hemolytic uremic syndro...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 05/15/10 - 04/30/11

DESCRIPTION (provided by applicant): Acinetobacter baumannii (A. baumannii) is a human pathogen responsible for recent increases in nosocomial infections of both military and civilian populations. Further emergence of the pathogen's broad resistance to available antibiotics has emphasized the need for truly novel antibacterial therapeutics. We h...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-115
Budget: 04/01/10 - 03/31/11

DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop a platform that broadly enables the generation of a new class of anti-viral therapeutics that recruit and activate the innate immunity system to attack specifically human cells infected with targeted viral pathogens. The platform deploys a recently discover...

Load More